|Bid||18.80 x 2200|
|Ask||18.81 x 1400|
|Day's Range||18.71 - 18.93|
|52 Week Range||5.25 - 19.48|
|Beta (5Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.67|
NEW YORK, NY / ACCESSWIRE / January 20, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders ...
NEW YORK, Jan. 20, 2020 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cincinnati Bell Inc. (NYSE: CBB) The.
WILMINGTON, Del., Jan. 15, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Dermira, Inc. (NASDAQ GS: DERM) regarding possible breaches of fiduciary.
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Dermira, Inc. (NASDAQ: DERM), Primo Water Corporation (NASDAQ: PRMW), Hexcel Corporation (NYSE: HXL), and Pope Resources, A Delaware Partnership (NASDAQ: POPE). Additional information about each potential action can be found at the link provided.
Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Shareholders should contact the firm immediately as there may be only a small window of time to enforce your rights:
What a difference a year makes. The start of the annual J.P. Morgan Healthcare investor conference in 2019 brought a double-header of giant deals. In 2020, there was almost nothing.
BALA CYNWYD, PA / ACCESSWIRE / January 13, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Dermira, Inc. ("Dermira" ...
(Bloomberg) -- Biotechnology companies slid Monday as big mergers failed to materialize from one of the sector’s most heralded events of the year.The iShares Nasdaq Biotechnology exchange traded fund fell as much as 1.8%, the biggest intraday drop since Oct. 8, as the JPMorgan Healthcare Conference kicked off in San Francisco. One of the biggest deals to come out ahead of the meeting is Teladoc Health Inc.’s $600 million purchase of closely held InTouch Health, a far cry from Bristol-Myers Squibb Co.’s $74 billion tie-up with Celgene Corp. before last year’s event.Eli Lilly & Co.’s $1.1 billion deal for Dermira Inc. on Friday also failed to ignite investor enthusiasm, when the deal came in at a 2.2% premium to Dermira’s Thursday closing price. The cash offer for $18.75 a share was less then half the stock’s record high close of $38.03 in March 2017.“The thing I worry about coming into JPM is that even if we have a couple buyouts, what happens to the other stocks that are priced for perfection?” independent investor Brad Loncar said in a meeting Sunday before the conference started. “Last year we came into this conference with the worst expectations I’ve ever seen and there were buyouts that eased those concerns, but this year we have some of the highest expectations I’ve ever seen.”Biotech has been trying to close the gap with the broader market and anticipation has been building that the world’s biggest drugmakers will continue to snap up their small-cap brethren after 2019’s banner year. In a report Monday, professional services firm EY said the health industry had more than $1 trillion in “firepower” that should deliver another strong year for deals. And there’s no shortage of needs when it comes to biotech investors’ wish lists.Some of the companies that frequently appear at the top of analysts’ M&A lists were among the biggest decliners Monday. Iovance Biotherapeutics Inc. plunged 15% while Intercept Pharmaceuticals Inc. slid as much as 8.5% and Seattle Genetics Inc. fell as much as 7.1%. Uniqure NV, which Bloomberg reported was exploring options including a sale in June, fell as much as 9.7%.(Updates to add Dermira details in third paragraph)To contact the reporters on this story: Cristin Flanagan in New York at email@example.com;Bailey Lipschultz in New York at firstname.lastname@example.orgTo contact the editor responsible for this story: Catherine Larkin at email@example.comFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.
NEW YORK, NY / ACCESSWIRE / January 13, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Dermira, Inc. ("Dermira" or the "Company") ...
Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
NEW YORK, NY / ACCESSWIRE / January 11, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cincinnati Bell Inc. (NYSE:CBB) The investigation concerns ...
Life sciences companies like to release a flurry of news in the days ahead of the giant J.P. Morgan Healthcare Conference in San Francisco to create fresh nuggets for potential investors and partners to gnaw on. Yet too much noise sometimes can hurt their message.
A Lilly executive says the $1.1 billion all-cash deal is fair, but the stock price indicates investors anticipate a higher valuation.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dermira, Inc. ("DERM" or the "Company") (NASDAQ: DERM) in connection with the proposed acquisition of the Company by Eli Lilly and Company ("LLY") (NYSE: LLY). Under the terms of the acquisition agreement, DERM shareholders will receive $18.75 for each share they own.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Dermira, Inc. ("Dermira" or the "Company") (Nasdaq: DERM) relating to the sale of the Company to Eli Lilly and Company. Under the terms of the sale, Dermira shareholders will receive $18.75 in cash for each share of Dermira common stock owned.
WILMINGTON, DE / ACCESSWIRE / January 10, 2020 / Rigrodsky & Long, P.A.: Do you own shares of Dermira, Inc. (NASDAQ GS: DERM )? Did you purchase any of your shares prior to January 10, 2020? Do you think ...
NEW YORK, Jan. 10, 2020 -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dermira, Inc. (NASDAQ: DERM) to Eli Lilly and Company (“Eli.
Rowley Law PLLC is investigating potential securities law violations by Dermira, Inc. (NASDAQ: DERM) and its board of directors concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Stockholders will receive $18.75 per share of Dermira, Inc. common stock that they hold. The transaction is valued at approximately $1.1 billion and is expected to close in the first quarter of 2020.
Lilly will pay $18.75 per Dermira share, or a 2.2% premium to Dermira's last closing price. It said the price represented a premium of about 86% to Dermira's 60-day volume-weighted average trading price including Friday's closing price.
Eli Lilly said it is buying a small biotech firm called Dermira in a $1.1 billion all-cash deal that would give it a promising drug for atopic dermatitis that is in Phase 3 clinical trials.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Benzinga Pro's Stocks To Watch For Friday Eli Lilly (LLY) - Shares were quiet Friday morning despite news the company will purchase Dermira (DERM) for $18.75/share in cash. Dermira shares were up about ...
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dermira, Inc. (NASDAQ: DERM) ("Dermira") breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Company ("Lilly").